Literature DB >> 33252253

The linearized disposition index augments understanding of treatment effects in diabetes.

Amanda J Kile1, Clarissa Hanna1, Tamara S Hannon1, M Sue Kirkman2, Robert V Considine1, Yash Patel3, Kieren J Mather1.   

Abstract

The disposition index, calculated by multiplying measures of insulin secretion and insulin sensitivity, is widely applied as a sensitivity-adjusted measure of insulin secretion. We have recently shown that linearizing the underlying relationship uniquely permits identification of terms relating to maximal insulin secretion capacity and the secretion-coupling relationship, with both terms separately contributing to differences in the secretion-sensitivity relationship across gradations of glycemia. Here, we demonstrate the application of this linearized equation to the evaluation of treatment-induced changes in the insulin secretion-sensitivity relationship. We applied a combination of repeated-measures multivariate linear regression (evaluating treatment-induced changes in the joint relationship of insulin sensitivity and secretion) plus mixed-model repeated measures (evaluating treatment effects on maximal secretion capacity and on the secretion-sensitivity coupling slope) and compared against a usual application of the disposition index calculated from the same measurements. This novel approach allows a more informative description of treatment-induced changes compared with the usual disposition index, including isolating the source of change within the mutually adjusted relationship and identifying treatment-induced changes in the secretion-sensitivity coupling slope and in maximal insulin secretion. Application of this linearized approach provides an expanded understanding of treatment-induced changes in the insulin sensitivity-secretion relationship.NEW & NOTEWORTHY The linearized insulin secretion-sensitivity relationship allows separate evaluation of the secretion-sensitivity slope and of maximal insulin secretion. Here, we demonstrate the application of this methodology to the evaluation of clinical trial data, showing that it provides an expanded understanding of treatment-induced changes compared with the disposition index.

Entities:  

Keywords:  disposition index; insulin secretion; insulin sensitivity; methodology

Mesh:

Year:  2020        PMID: 33252253      PMCID: PMC8194409          DOI: 10.1152/ajpendo.00397.2020

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  17 in total

1.  The disposition index: from individual to population approach.

Authors:  Paolo Denti; Gianna Maria Toffolo; Claudio Cobelli
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-06-05       Impact factor: 4.310

2.  The hyperbolic law--a 25-year perspective.

Authors:  M Stumvoll; P A Tataranni; C Bogardus
Journal:  Diabetologia       Date:  2005-02       Impact factor: 10.122

3.  Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2019-06-09       Impact factor: 19.112

4.  Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function.

Authors:  S E Kahn; R L Prigeon; D K McCulloch; E J Boyko; R N Bergman; M W Schwartz; J L Neifing; W K Ward; J C Beard; J P Palmer
Journal:  Diabetes       Date:  1993-11       Impact factor: 9.461

5.  Changes in Weight and Glucose Can Protect Against Progression in Early Diabetes Independent of Improvements in β-Cell Function.

Authors:  Y R Patel; M S Kirkman; R V Considine; T S Hannon; K J Mather
Journal:  J Clin Endocrinol Metab       Date:  2016-08-17       Impact factor: 5.958

6.  Profound defects in β-cell function in screen-detected type 2 diabetes are not improved with glucose-lowering treatment in the Early Diabetes Intervention Program (EDIP).

Authors:  Tamara S Hannon; M S Kirkman; Yash R Patel; Robert V Considine; Kieren J Mather
Journal:  Diabetes Metab Res Rev       Date:  2014-11       Impact factor: 4.876

7.  Within-subject variability of measures of beta cell function derived from a 2 h OGTT: implications for research studies.

Authors:  K M Utzschneider; R L Prigeon; J Tong; F Gerchman; D B Carr; S Zraika; J Udayasankar; B Montgomery; A Mari; S E Kahn
Journal:  Diabetologia       Date:  2007-10-11       Impact factor: 10.122

8.  Linearization of the Disposition Index equation allows evaluation of secretion-sensitivity coupling slopes.

Authors:  Kieren J Mather; Melinda Chen; Tamara S Hannon
Journal:  J Diabetes Complications       Date:  2020-04-28       Impact factor: 2.852

9.  Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.

Authors:  Steven E Kahn; John M Lachin; Bernard Zinman; Steven M Haffner; R Paul Aftring; Gitanjali Paul; Barbara G Kravitz; William H Herman; Giancarlo Viberti; Rury R Holman
Journal:  Diabetes       Date:  2011-03-17       Impact factor: 9.461

10.  β-Cell function improvements in grade I/II obese subjects with type 2 diabetes 1 month after biliopancreatic diversion: results from modeling analyses of oral glucose tolerance tests and hyperglycemic clamp studies.

Authors:  Ana Carolina Junqueira Vasques; José Carlos Pareja; Maria da Saude de Oliveira; Fernanda Satake Novaes; Marcelo Miranda de Oliveira Lima; Élinton A Chaim; Francesca Piccinini; Chiara Dalla Man; Claudio Cobelli; Bruno Geloneze
Journal:  Diabetes Care       Date:  2013-10-17       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.